(+)-Etomoxir sodium salt hydrate
SIGMA/E1905 - ≥98% (HPLC), powder
Synonym: R(+)
CAS Number: 828934-41-4 (anhydrous)
Empirical Formula (Hill Notation): C15H18ClO4 · Na · H2O
Molecular Weight: 338.76
MDL Number: MFCD11044452
Linear Formula: C15H18ClO4 · Na · H2O
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white |
| form | powder |
| InChI | 1S/C15H19ClO4.Na.H2O/c16- |
| InChI key | WENJLJJSJDAJDN-QCUBGVIVSA |
| Quality Level | 100 ![]() |
| SMILES string | O.[Na+].[O-]C(=O)[C@@]2(C |
| solubility | H2O: freely soluble |
| storage temp. | 2-8°C |
| Application: | (+)-Etomoxir sodium salt hydrate has been used as an inhibitor of carnitine palmitoyltransferase 1 (CPT-1) in breast tumor cell lines and mice tumor. It has also been used as an inhibitor of fatty acid oxidation in human primary prostate epithelial cells and lymphocytes. |
| Biochem/physiol Actions: | Irreversible O-carnitine palmitoyltransferase-1 (CPT-1) inhibitor; PPARα activator |
| General description: | (+)-Etomoxir sodium salt hydrate belongs to oxirane carboxylic acid group of compounds and mediates metabolic channeling of fatty acid precursors. It favors oxidative stress in T cells and prevents T cell differentiation. It inhibits fatty acid oxidation and promotes hunger and food intake. Etomoxir impairs myeloid-derived suppressor cells mediated tumor and could have potential therapeutic potential. |
| Packaging: | 5, 25 mg in glass bottle |
| Packaging: | Store tightly sealed, protected from exposure to light |
| Symbol | GHS06 |
| Signal word | Danger |
| Hazard statements | H301 |
| Precautionary statements | P264 - P270 - P301 + P310 + P330 - P405 - P501 |
| Hazard Codes | Xn |
| Risk Statements | 22 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |


